Biotech Values

[LS89]

I hope ENTA can secure one or two partnerships next year to demonstrate its potential.
They have two solid individuals in the CSO and CBO roles, but neither have delivered on the licensing front. Seems like there is some redundancy between those roles and an opportunity to either combine the roles and reduce headcount or combine the roles and bring in a real heavy hitter.